First approved in late 2016, Spinraza has become one of the most important medicines in Biogen’s arsenal, accounting for about a fifth of the company’s total product revenue.
Recently, though, the Spinraza franchise hasn’t fared as well due to competitive threats.
A second treatment, the Zolgensma gene therapy from Novartis, became available in 2019. Then a third option arrived the following year with Evrysdi, an oral medication developed by Roche. On its most recent earnings report, Biogen pointed to this more crowded market as the main reason why third quarter Spinraza revenue in the U.S. had fallen 23%.
